Hemodynamics, fluids & transfusion
Angiotensin II for the Treatment of Refractory Shock: A Matched Analysis*
Authors' conclusion
In patients with severe shock, angiotensin II was not associated with improved mortality or organ dysfunction and was not associated with an increased rate of adverse events.
Study context
- Population
- Adults with shock admitted to an ICU and requiring vasopressor support, multiple ICUs of a large university-based hospital
- Participants
- 813 adults
- Exposure
- Angiotensin II vs equivalent doses of nonangiotensin II vasopressors
- Outcome
- 30-day mortality
- Follow-up
- 30 days
Methodological detailsmatched analysis, historical and concurrent controls, single-centre
- Matched analysis
- Historical and concurrent controls
- Single-centre
Main finding
As reported in the abstract
P = 0.292
Observational data: associations, not effects.
Secondary outcomes
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Kidney replacement therapy after enrollment | 1.39 (0.88–2.19) | P = 0.158 | |
| Mechanical ventilation after enrollment | 1.50 (0.41–5.51) | P = 0.539 | |
| 0.20.5125Odds ratio (log scale) |
| Outcome | P value |
|---|---|
| 90-day mortality | P = 0.440 |
90-day mortality
- Similar 90-day mortality (65% vs 63%)
Change in SOFA scores over 5-day monitoring after enrollment
- Similar
Safety
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Thrombotic events | 1.02 (0.71–1.48) | P = 0.912 | |
| 0.512Odds ratio (log scale) |
Original publication
Angiotensin II for the Treatment of Refractory Shock: A Matched Analysis*. Crit Care Med. Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →